Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non-small cell lung cancer: a meta-analysis.

BMC Cancer · 2018 · PMC6090934 · PMID 30068310

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Our results also showed a trend for prolonged median PFS (gefitinib group, 7.1 months vs. 4.9 months; erlotinib group, 7.7 months vs. 3.4 months) and OS (gefitinib group, 19.1 months vs. 14.0 months; erlotinib group, 15.5 months vs. 12.7 months) in patients with adenocarcinoma as compared with squamous-included NSCLC.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.